RU2019138177A - Производные 2-аминохинолина - Google Patents
Производные 2-аминохинолина Download PDFInfo
- Publication number
- RU2019138177A RU2019138177A RU2019138177A RU2019138177A RU2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- salt
- quinolin
- ethoxymethyl
- imidazo
- Prior art date
Links
- 150000005013 2-aminoquinolines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 30
- -1 4 - ((4-amino-2-ethoxy-methyl-1-methyl-1H-imidazo [4,5-c] quinolin-9-yl) oxy) -2-methylbutan-2-ol Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 4
- HSEMFIZWXHQJAE-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 claims 4
- VOZORYRGGNVPJW-UHFFFAOYSA-N 10-oxa-4,14-diazatricyclo[7.5.1.05,15]pentadeca-1(15),2,4,6,8,11,13-heptaen-12-ol Chemical compound N1=CC=C2C=3C(=CC=CC1=3)OC=C(C=N2)O VOZORYRGGNVPJW-UHFFFAOYSA-N 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- GKFPOIUULJGQPN-UHFFFAOYSA-N 1-[4-amino-2-(2-hydroxyethyl)-9-methoxyimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)(O)C)CCO)OC GKFPOIUULJGQPN-UHFFFAOYSA-N 0.000 claims 1
- WZRGIGQHNDGFIG-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxy-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2C)COCC)OCC(C)(O)C WZRGIGQHNDGFIG-UHFFFAOYSA-N 0.000 claims 1
- QOYVKJKPMJGWOA-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-9-methoxyimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)(O)C)COCC)OC QOYVKJKPMJGWOA-UHFFFAOYSA-N 0.000 claims 1
- YHYFYUKNKQMNOK-UHFFFAOYSA-N 1-[4-amino-9-methoxy-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)(O)C)CCOC)OC YHYFYUKNKQMNOK-UHFFFAOYSA-N 0.000 claims 1
- BLYHFWNPCIGTHH-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]propan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)COCC)OCC(C)O BLYHFWNPCIGTHH-UHFFFAOYSA-N 0.000 claims 1
- CPAODTBRTBTGDI-UHFFFAOYSA-N 10-oxa-4,14-diazatricyclo[7.5.1.05,15]pentadeca-1(15),2,4,6,8,13-hexaen-12-one Chemical compound N1=CC=C2C=3C(=CC=CC1=3)OCC(C=N2)=O CPAODTBRTBTGDI-UHFFFAOYSA-N 0.000 claims 1
- UEFOMEYNTZNHQB-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(2-methylpropoxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OCC(C)C)N)N=1)C UEFOMEYNTZNHQB-UHFFFAOYSA-N 0.000 claims 1
- HJNCPVOAGHSHPK-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(2-morpholin-4-ylethoxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OCCN2CCOCC2)N)N=1)C HJNCPVOAGHSHPK-UHFFFAOYSA-N 0.000 claims 1
- XDTSMYJPPAAGLU-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(2-propan-2-yloxyethoxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OCCOC(C)C)N)N=1)C XDTSMYJPPAAGLU-UHFFFAOYSA-N 0.000 claims 1
- AZTFHSKKWCHQKW-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(oxolan-3-yloxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC2COCC2)N)N=1)C AZTFHSKKWCHQKW-UHFFFAOYSA-N 0.000 claims 1
- IXJQFWNIWIELNR-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-piperidin-4-yloxyimidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC2CCNCC2)N)N=1)C IXJQFWNIWIELNR-UHFFFAOYSA-N 0.000 claims 1
- UIVUUEFCKIJLNB-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-propan-2-yloxyimidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC(C)C)N)N=1)C UIVUUEFCKIJLNB-UHFFFAOYSA-N 0.000 claims 1
- WAFQYUYNGVIVNG-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-pyrrolidin-3-yloxyimidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC2CNCC2)N)N=1)C WAFQYUYNGVIVNG-UHFFFAOYSA-N 0.000 claims 1
- XKMXEEZJOCABSN-UHFFFAOYSA-N 2-(ethoxymethyl)-9-(2-methylpropoxy)-3H-imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1NC2=C(C(=NC=3C=CC=C(C2=3)OCC(C)C)N)N=1 XKMXEEZJOCABSN-UHFFFAOYSA-N 0.000 claims 1
- HRWIFFDHQMFGNN-UHFFFAOYSA-N 2-(ethoxymethyl)-9-(2-propan-2-yloxyethoxy)-3H-imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1NC2=C(C(=NC=3C=CC=C(C2=3)OCCOC(C)C)N)N=1 HRWIFFDHQMFGNN-UHFFFAOYSA-N 0.000 claims 1
- YGDTZZRKAQEXFO-UHFFFAOYSA-N 2-(ethoxymethyl)-9-(3-methylbutoxy)-3H-imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1NC2=C(C(=NC=3C=CC=C(C2=3)OCCC(C)C)N)N=1 YGDTZZRKAQEXFO-UHFFFAOYSA-N 0.000 claims 1
- PLKWRVIXFITHLR-UHFFFAOYSA-N 2-(ethoxymethyl)-9-methoxy-1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC)N)N=1)CC(C)C PLKWRVIXFITHLR-UHFFFAOYSA-N 0.000 claims 1
- VUJGOQDZTMOKFV-UHFFFAOYSA-N 2-(ethoxymethyl)-9-methoxy-1-(2-propan-2-yloxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC)N)N=1)CCOC(C)C VUJGOQDZTMOKFV-UHFFFAOYSA-N 0.000 claims 1
- KEXGXOJEMYADSG-UHFFFAOYSA-N 2-butyl-9-(3-methylbutoxy)pyrazolo[3,4-c]quinolin-4-amine Chemical class C(CCC)N1N=C2C(=NC=3C=CC=C(C=3C2=C1)OCCC(C)C)N KEXGXOJEMYADSG-UHFFFAOYSA-N 0.000 claims 1
- FLKJVZNZWBSCNA-UHFFFAOYSA-N 4-[4-amino-2-(ethoxymethyl)-1-(2-methylpropyl)imidazo[4,5-c]quinolin-9-yl]oxy-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)C)COCC)OCCC(C)(O)C FLKJVZNZWBSCNA-UHFFFAOYSA-N 0.000 claims 1
- OCIADYZDROIKDL-UHFFFAOYSA-N 4-[4-amino-2-(ethoxymethyl)-9-methoxyimidazo[4,5-c]quinolin-1-yl]-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CCC(C)(O)C)COCC)OC OCIADYZDROIKDL-UHFFFAOYSA-N 0.000 claims 1
- ITPHJKRCXVELDB-UHFFFAOYSA-N 4-[[4-amino-2-(2-methoxyethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)CCOC)OCCC(C)(O)C ITPHJKRCXVELDB-UHFFFAOYSA-N 0.000 claims 1
- REWHSGXVPGPMCX-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)COCC)OCCC(C)(O)C REWHSGXVPGPMCX-UHFFFAOYSA-N 0.000 claims 1
- JWARRFKQCPVLSR-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]butan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)COCC)OCCC(C)O JWARRFKQCPVLSR-UHFFFAOYSA-N 0.000 claims 1
- AMPBTPQXPBRJCY-UHFFFAOYSA-N 4-amino-2-(3-methylbutyl)pyrazolo[3,4-c]quinolin-9-ol Chemical class NC1=NC=2C=CC=C(C=2C=2C1=NN(C=2)CCC(C)C)O AMPBTPQXPBRJCY-UHFFFAOYSA-N 0.000 claims 1
- PCQZTOCRIVZHOB-UHFFFAOYSA-N 4-amino-3H-pyrazolo[3,4-c]quinolin-9-ol Chemical class NC1=NC=2C=CC=C(C=2C=2C1=NNC=2)O PCQZTOCRIVZHOB-UHFFFAOYSA-N 0.000 claims 1
- FSIDHUJJSWXKCQ-UHFFFAOYSA-N 9-(3-methylbutoxy)-2-(3-methylbutyl)pyrazolo[3,4-c]quinolin-4-amine Chemical class C(CC(C)C)N1N=C2C(=NC=3C=CC=C(C=3C2=C1)OCCC(C)C)N FSIDHUJJSWXKCQ-UHFFFAOYSA-N 0.000 claims 1
- HTLWKFKYFYPSCH-UHFFFAOYSA-N 9-methoxy-3H-imidazo[4,5-c]quinolin-4-amine Chemical class COC=1C=2C3=C(C(=NC=2C=CC=1)N)N=CN3 HTLWKFKYFYPSCH-UHFFFAOYSA-N 0.000 claims 1
- ICOJRQWKSUISLK-UHFFFAOYSA-N 9-methoxy-3H-pyrazolo[3,4-c]quinolin-4-amine Chemical class COc1cccc2nc(N)c3n[nH]cc3c12 ICOJRQWKSUISLK-UHFFFAOYSA-N 0.000 claims 1
- BQICROVULNIKFQ-UHFFFAOYSA-N N-[2-[2-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxyethoxy]ethyl]methanesulfonamide Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2C)COCC)OCCOCCNS(=O)(=O)C BQICROVULNIKFQ-UHFFFAOYSA-N 0.000 claims 1
- IXGVMYREGNTOBW-UHFFFAOYSA-N N-[3-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxypropyl]acetamide Chemical class C(C)(=O)NCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC IXGVMYREGNTOBW-UHFFFAOYSA-N 0.000 claims 1
- FQDKRRYLMFABOK-UHFFFAOYSA-N N-[3-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxypropyl]methanesulfonamide Chemical class CS(=O)(=O)NCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC FQDKRRYLMFABOK-UHFFFAOYSA-N 0.000 claims 1
- KPRPJCGNUMXCGE-UHFFFAOYSA-N N-[3-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxypropyl]octadecanamide Chemical class C(CCCCCCCCCCCCCCCCC)(=O)NCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC KPRPJCGNUMXCGE-UHFFFAOYSA-N 0.000 claims 1
- DUCMVTIPWNWNEK-UHFFFAOYSA-N N-[4-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxybutyl]acetamide Chemical class C(C)(=O)NCCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC DUCMVTIPWNWNEK-UHFFFAOYSA-N 0.000 claims 1
- XSTUUKIVJMZMLY-UHFFFAOYSA-N N-[4-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxybutyl]methanesulfonamide Chemical class CS(=O)(=O)NCCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC XSTUUKIVJMZMLY-UHFFFAOYSA-N 0.000 claims 1
- NDNROUSBPSFIOA-UHFFFAOYSA-N N-[4-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxybutyl]octadecanamide Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2C)COCC)OCCCCNC(CCCCCCCCCCCCCCCCC)=O NDNROUSBPSFIOA-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710287322.2 | 2017-04-27 | ||
| CN201710287322.2A CN108794467A (zh) | 2017-04-27 | 2017-04-27 | 2-氨基-喹啉衍生物 |
| PCT/CN2018/084674 WO2018196823A1 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019138177A3 RU2019138177A3 (enExample) | 2021-05-27 |
| RU2019138177A true RU2019138177A (ru) | 2021-05-27 |
Family
ID=63918846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019138177A RU2019138177A (ru) | 2017-04-27 | 2018-04-26 | Производные 2-аминохинолина |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11053240B2 (enExample) |
| EP (1) | EP3615539B1 (enExample) |
| JP (1) | JP7179357B2 (enExample) |
| KR (1) | KR102541238B1 (enExample) |
| CN (3) | CN118515666A (enExample) |
| AU (1) | AU2018259831B2 (enExample) |
| BR (1) | BR112019022246A2 (enExample) |
| CA (1) | CA3061187A1 (enExample) |
| IL (1) | IL270219B (enExample) |
| MX (1) | MX2019012676A (enExample) |
| RU (1) | RU2019138177A (enExample) |
| SG (1) | SG11201909325RA (enExample) |
| WO (1) | WO2018196823A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| SG11201605449YA (en) | 2014-01-10 | 2016-08-30 | Birdie Biopharmaceuticals Inc | Compounds and compositions for immunotherapy |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CA3029902A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| AU2020231822A1 (en) * | 2019-03-07 | 2021-08-26 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| WO2021177679A1 (ko) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
| JP7690221B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| EP4194010A4 (en) | 2020-08-04 | 2025-03-26 | Progeneer Inc. | Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof |
| WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| IL305029A (en) * | 2021-02-22 | 2023-10-01 | Univ Minnesota | Immunomodulators and immunomodulator conjugates |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| WO2023283213A1 (en) | 2021-07-07 | 2023-01-12 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
| JP2024537824A (ja) | 2021-10-01 | 2024-10-16 | インサイト・コーポレイション | ピラゾロキノリンｋｒａｓ阻害剤 |
| MX2024004444A (es) | 2021-10-14 | 2024-05-08 | Incyte Corp | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| HU230586B1 (hu) | 1999-06-25 | 2017-02-28 | Genentech, Inc. | Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| JP2008531580A (ja) | 2000-12-08 | 2008-08-14 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答修飾因子の標的化送達のための組成物および方法 |
| UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| EP1455700A4 (en) | 2001-11-16 | 2007-02-14 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS |
| NZ533628A (en) | 2001-11-27 | 2006-07-28 | Anadys Pharmaceuticals Inc | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
| EP1590348A1 (en) | 2002-12-20 | 2005-11-02 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004062603A2 (en) | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Methods of treating lung diseases |
| US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
| WO2005025583A2 (en) | 2003-09-05 | 2005-03-24 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| EP1696912B1 (en) | 2003-10-03 | 2016-05-11 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| JP2007517055A (ja) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答の増強 |
| WO2005092893A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | ９置換−８−オキソアデニン化合物 |
| EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| EP1809671B1 (en) | 2004-11-09 | 2014-07-16 | University Of Southern California | CpG/antibody conjugate against cancer |
| US8461174B2 (en) | 2004-12-30 | 2013-06-11 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
| JP2008531590A (ja) | 2005-02-24 | 2008-08-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カリウムイオンチャンネル開口薬としての新規なキノリン誘導体 |
| RU2007141067A (ru) | 2005-04-14 | 2009-05-20 | Мерк Патент ГмбХ (DE) | Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях |
| CN101203241B (zh) | 2005-04-19 | 2012-02-22 | 西雅图基因公司 | 人源化抗-cd70结合物和其应用 |
| JP5185813B2 (ja) | 2005-04-26 | 2013-04-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癌免疫治療のための組成物および方法 |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TWI404537B (zh) | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| CA2621502A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| US8951528B2 (en) | 2006-02-22 | 2015-02-10 | 3M Innovative Properties Company | Immune response modifier conjugates |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| PT2845866T (pt) | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
| NZ577440A (en) | 2006-12-21 | 2011-12-22 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| PL2125007T3 (pl) | 2007-02-07 | 2014-07-31 | Univ California | Koniugaty syntetycznych agonistów TLR i ich zastosowania |
| PT2155743E (pt) | 2007-05-08 | 2012-10-30 | Astrazeneca Ab | Imidazoquinolinas com propriedades imunomoduladoras |
| WO2009018500A1 (en) | 2007-07-31 | 2009-02-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| GB0715428D0 (en) * | 2007-08-08 | 2007-09-19 | Imp Innovations Ltd | Compositions and uses thereof |
| JP5410434B2 (ja) | 2007-09-28 | 2014-02-05 | バインド セラピューティックス インコーポレイテッド | ナノ粒子を用いた癌細胞の標的化 |
| MX2010007699A (es) | 2008-01-15 | 2010-08-04 | Meda Ab | Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina. |
| CA2713137C (en) | 2008-01-25 | 2017-10-24 | Hadasit Medical Research Services And Development Ltd. | Targeting of innate immune response to tumor site |
| US20090202626A1 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
| HUE035182T2 (hu) | 2008-03-18 | 2018-05-02 | Genentech Inc | Anti-HER2 antitest-hatóanyag-konjugátum és pertuzumab kombinációi |
| EP2316032A1 (en) | 2008-08-20 | 2011-05-04 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8 |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| PE20120106A1 (es) | 2008-12-09 | 2012-02-20 | Gilead Sciences Inc | Moduladores de receptores tipo toll |
| PL2427485T3 (pl) | 2009-05-07 | 2017-10-31 | Immunocellular Therapeutics Ltd | Epitopy CD133 |
| WO2010132622A2 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
| US20110077263A1 (en) | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| WO2011084725A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| WO2011084726A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| ES2608475T3 (es) | 2010-04-13 | 2017-04-11 | Celldex Therapeutics, Inc. | Anticuerpos que se unen a cd27 humana y usos de los mismos |
| NO2575876T3 (enExample) | 2010-05-26 | 2018-05-05 | ||
| AR082686A1 (es) | 2010-08-13 | 2012-12-26 | Baylor Res Inst | Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos |
| NZ608673A (en) | 2010-10-01 | 2015-04-24 | Univ Pennsylvania | Therapeutic use of a tlr agonist and combination therapy |
| EP2648719A1 (en) | 2010-12-09 | 2013-10-16 | F.Hoffmann-La Roche Ag | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
| EP3207930A1 (en) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| CN103458930B (zh) | 2011-02-01 | 2019-10-15 | 健玛保 | 针对cd74的人抗体和抗体-药物缀合物 |
| TW201247706A (en) | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| KR101649610B1 (ko) | 2011-04-21 | 2016-08-19 | 오리제니스 게엠베하 | 키나아제 억제제로서의 헤테로사이클릭 화합물 |
| UY34032A (es) * | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| AU2012290121B2 (en) | 2011-08-01 | 2015-11-26 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
| US9120763B2 (en) | 2011-08-11 | 2015-09-01 | Huntsman Advanced Materials Americas Llc | Method for producing benzoxazine compounds |
| CN103957939A (zh) | 2011-09-19 | 2014-07-30 | 约翰霍普金斯大学 | 癌症免疫治疗 |
| WO2013063277A1 (en) | 2011-10-25 | 2013-05-02 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CN104661683A (zh) | 2011-11-09 | 2015-05-27 | 埃森德生物制药有限公司 | 免疫调节缀合物 |
| WO2013166110A1 (en) | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| AR092219A1 (es) | 2012-08-23 | 2015-04-08 | Seattle Genetics Inc | Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7 |
| US9637491B2 (en) * | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
| US10000482B2 (en) * | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
| EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| SG11201605449YA (en) | 2014-01-10 | 2016-08-30 | Birdie Biopharmaceuticals Inc | Compounds and compositions for immunotherapy |
| AU2015279738A1 (en) | 2014-06-25 | 2016-12-22 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| DK3345907T3 (da) | 2015-09-01 | 2020-06-22 | Taiho Pharmaceutical Co Ltd | Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf |
| US10821127B2 (en) | 2015-11-09 | 2020-11-03 | Shaperon Inc. | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
| EP3846807B1 (en) | 2018-09-07 | 2023-08-02 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
| CN113613641A (zh) | 2018-12-26 | 2021-11-05 | 博笛生物科技有限公司 | 用于治疗癌症的免疫调节组合和方法 |
| US20220175762A1 (en) | 2019-03-15 | 2022-06-09 | Birdie Biopharmaceuticals, Inc. | Immune modulatory compositions and methods for treating cancers |
| WO2022047083A1 (en) | 2020-08-26 | 2022-03-03 | Birdie Pharmaceuticals, Inc. | Cancer treatment with tlr agonist |
-
2017
- 2017-04-27 CN CN202410623331.4A patent/CN118515666A/zh active Pending
- 2017-04-27 CN CN201710287322.2A patent/CN108794467A/zh active Pending
-
2018
- 2018-04-26 US US16/608,581 patent/US11053240B2/en not_active Expired - Fee Related
- 2018-04-26 EP EP18792253.9A patent/EP3615539B1/en active Active
- 2018-04-26 SG SG11201909325R patent/SG11201909325RA/en unknown
- 2018-04-26 CN CN201880014574.0A patent/CN110637018B/zh active Active
- 2018-04-26 MX MX2019012676A patent/MX2019012676A/es unknown
- 2018-04-26 IL IL270219A patent/IL270219B/en unknown
- 2018-04-26 BR BR112019022246-4A patent/BR112019022246A2/pt not_active IP Right Cessation
- 2018-04-26 WO PCT/CN2018/084674 patent/WO2018196823A1/en not_active Ceased
- 2018-04-26 AU AU2018259831A patent/AU2018259831B2/en not_active Ceased
- 2018-04-26 CA CA3061187A patent/CA3061187A1/en active Pending
- 2018-04-26 JP JP2019558496A patent/JP7179357B2/ja active Active
- 2018-04-26 KR KR1020197033158A patent/KR102541238B1/ko active Active
- 2018-04-26 RU RU2019138177A patent/RU2019138177A/ru not_active Application Discontinuation
-
2021
- 2021-05-07 US US17/315,162 patent/US20210261549A1/en not_active Abandoned
- 2021-05-07 US US17/315,156 patent/US11834448B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020517711A (ja) | 2020-06-18 |
| US11053240B2 (en) | 2021-07-06 |
| CA3061187A1 (en) | 2018-11-01 |
| KR20190141174A (ko) | 2019-12-23 |
| EP3615539B1 (en) | 2023-08-09 |
| JP7179357B2 (ja) | 2022-11-29 |
| US20210261549A1 (en) | 2021-08-26 |
| EP3615539A4 (en) | 2020-08-19 |
| IL270219A (enExample) | 2019-12-31 |
| US20200055851A1 (en) | 2020-02-20 |
| IL270219B (en) | 2022-09-01 |
| EP3615539A1 (en) | 2020-03-04 |
| CN110637018B (zh) | 2025-06-06 |
| KR102541238B1 (ko) | 2023-06-08 |
| CN110637018A (zh) | 2019-12-31 |
| RU2019138177A3 (enExample) | 2021-05-27 |
| BR112019022246A2 (pt) | 2020-08-11 |
| CN108794467A (zh) | 2018-11-13 |
| MX2019012676A (es) | 2020-02-05 |
| WO2018196823A1 (en) | 2018-11-01 |
| US11834448B2 (en) | 2023-12-05 |
| AU2018259831A1 (en) | 2019-10-31 |
| AU2018259831B2 (en) | 2022-06-16 |
| US20210261548A1 (en) | 2021-08-26 |
| SG11201909325RA (en) | 2019-11-28 |
| CN118515666A (zh) | 2024-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019138177A (ru) | Производные 2-аминохинолина | |
| JP2020517711A5 (enExample) | ||
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| RU2011147232A (ru) | Производное карбоновой кислоты | |
| ES2242782T3 (es) | Imidazoquinolinas sustituidas con tioeteres. | |
| RU2012138709A (ru) | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения | |
| JP2019509276A5 (enExample) | ||
| ME02124B (me) | Novi supstituisani imidazohinolini | |
| RU2013152788A (ru) | Амидные соединения и их фармацевтическое применение | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| AR059481A1 (es) | Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas. | |
| RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
| RU2015109706A (ru) | Новые производные азабензимидазол гексагидрофуро[3, 2-в]фурана | |
| JP2017530118A5 (enExample) | ||
| RU2012141536A (ru) | Имидазопиридины, композиции и способы применения | |
| RU2015120478A (ru) | Пери-карбинолы | |
| JP2016518434A5 (enExample) | ||
| RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| RU2015116953A (ru) | Новые соединения | |
| JP2012522766A5 (enExample) | ||
| AR116474A1 (es) | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV | |
| RU2015104830A (ru) | Соединения | |
| AR087212A1 (es) | ANTAGONISTAS DE CRTh2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220119 |